News
VBI Vaccines announces filing of NDS for 3-Antigen Hepatitis B vaccine to Health Canada.
VBI Vaccines Inc. announced the filing of a New Drug Submission (NDS) to Health Canada for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate, seeking approval in Canada for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.
VBI’s vaccine candidate is the only 3-antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and is approved for use in the United States under the name PreHevbrio [Hepatitis B Vaccine (Recombinant)], and in Israel under the name Sci-B-Vac. This vaccine candidate is not yet approved in Canada or Europe, where the regulatory submissions are still under review.
Condition: Hepatitis B
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.